DrugPatentWatch Database Preview
Drugs in Development Information for ISV-305
Email this page to a colleague
See Plans and PricingWhat is the development status for investigational drug ISV-305?
ISV-305 is an investigational drug.
There have been 15 clinical trials for ISV-305.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 4th 2019.
The most common disease conditions in clinical trials are Cataract, Inflammation, and Conjunctivitis. The leading clinical trial sponsors are InSite Vision, Bausch & Lomb Incorporated, and University of California, San Diego.
There are two US patents protecting this investigational drug and forty-two international patents.
Summary for ISV-305
| US Patents | 2,586 |
| International Patents | 42,845 |
| US Patent Applications | 4,479 |
| WIPO Patent Applications | 2,795 |
| Japanese Patent Applications | 18 |
| Clinical Trial Progress | Phase 3 (2019-12-04) |
| Vendors | 68 |
Recent Clinical Trials for ISV-305
| Title | Sponsor | Phase |
|---|---|---|
| Rib Fracture Analgesia Using Cryoanalgesia | Epimed International | Phase 4 |
| Rib Fracture Analgesia Using Cryoanalgesia | University of Florida | Phase 4 |
| Rib Fracture Analgesia Using Cryoanalgesia | University of California, San Diego | Phase 4 |
Clinical Trial Summary for ISV-305
Top disease conditions for ISV-305
Top clinical trial sponsors for ISV-305
US Patents for ISV-305
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ISV-305 | Start Trial | IBAT inhibitors for the treatment of liver diseases | Albireo AB (Gothenburg, SE) | Start Trial |
| ISV-305 | Start Trial | Methods and compositions for producing hepatocyte-like cells | The Board of Trustees of the Leland Stanford Junior University (Stanford, CA) | Start Trial |
| ISV-305 | Start Trial | Low, immune enhancing, dose mtor inhibitors and uses thereof | Novartis AG (Basel, CH) | Start Trial |
| ISV-305 | Start Trial | Substituted indole Mcl-1 inhibitors | Vanderbilt University (Nashville, TN) | Start Trial |
| ISV-305 | Start Trial | Salts of an epidermal growth factor receptor kinase inhibitor | Celgene CAR LLC (Pembroke, BM) | Start Trial |
| ISV-305 | Start Trial | 1-(4-pyrimidinyl)-1H-pyrrolo[3,2-c]pyridine derivatives as NIK inhibitors | Janssen Pharmaceutica NV (Beerse, BE) | Start Trial |
| ISV-305 | Start Trial | Pharmaceutical compounds | Cascadian Therapeutics, Inc. (Seattle, WA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ISV-305
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ISV-305 | Australia | 2011326871 | 2030-11-08 | Start Trial |
| ISV-305 | Brazil | 112013010157 | 2030-11-08 | Start Trial |
| ISV-305 | Canada | 2815749 | 2030-11-08 | Start Trial |
| ISV-305 | China | 103260625 | 2030-11-08 | Start Trial |
| ISV-305 | China | 105288580 | 2030-11-08 | Start Trial |
| ISV-305 | Cyprus | 1118125 | 2030-11-08 | Start Trial |
| ISV-305 | Denmark | 2637668 | 2030-11-08 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
